prednisone has been researched along with Bone Loss, Perimenopausal in 24 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| " We report a case of BRONJ in a patient following six years of oral BP administration for the management of osteoporosis, complicated by four years of prednisone therapy for pulmonary fibrosis." | 3.81 | Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis. ( Reiss, S; Sultan, D, 2015) |
| "All studied subjects (n=51) had postmenopausal osteoporosis, had been receiving long-term treatment with glucocorticoid plus estrogen or estrogen/progesterone and were randomly allocated either to a group receiving hPTH, 400 U/day (n=28), or to a control group (n=23)." | 2.71 | Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). ( Hurley, M; Lane, NE; Yao, W, 2005) |
| "Vancomycin was stopped." | 1.37 | [Strontium ranelate-induced DRESS syndrome]. ( Adamski, H; Chevrant-Breton, J; Colin, F; Dinulescu, M; Grimaud, H; Le Gall, F; Le Merlouette, M, 2011) |
| "Systemic mastocytosis is a rare and occasionally aggressive condition that raises major diagnostic challenges." | 1.32 | Aggressive systemic mastocytosis. ( Bertin, P; Inaoui, R; Jaccard, A; Petit, B; Trèves, R, 2003) |
| "Bone loss was evidenced in women with primary biliary cirrhosis compared with control age-matched women (Z-score: -0." | 1.31 | Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. ( Berenbaum, F; Chazouillères, O; Grandpierre, C; Le Gars, L; Poupon, R, 2002) |
| "Sacral insufficiency fractures developed in 4 of 386 patients." | 1.29 | Sacral insufficiency fractures in rheumatoid arthritis. ( Baker, MR; Place, HM; Troutner, JL; West, SG, 1994) |
| "A 54 year old, postmenopause female with pulmonary fibrosis on steroid therapy is studied for lumbar and sacral pain." | 1.28 | [Spontaneous fracture of the sacrum in patient with pulmonary fibrosis and steroid treatment]. ( Alvarado, A; Guzmán, L; Maluje, V, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 6 (25.00) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Herrera, I | 1 |
| Kam, Y | 1 |
| Whittaker, TJ | 1 |
| Champion, M | 1 |
| Ajlan, RS | 1 |
| Malochet-Guinamand, S | 1 |
| Lambert, C | 1 |
| Gossec, L | 1 |
| Soubrier, M | 1 |
| Dougados, M | 1 |
| Reiss, S | 1 |
| Sultan, D | 1 |
| Procianoy, F | 1 |
| Procianoy, E | 1 |
| Mok, CC | 1 |
| Ying, KY | 1 |
| To, CH | 1 |
| Ho, LY | 1 |
| Yu, KL | 1 |
| Lee, HK | 1 |
| Ma, KM | 1 |
| Le Merlouette, M | 1 |
| Adamski, H | 1 |
| Dinulescu, M | 1 |
| Le Gall, F | 1 |
| Colin, F | 1 |
| Grimaud, H | 1 |
| Chevrant-Breton, J | 1 |
| Roux, C | 1 |
| Reid, DM | 2 |
| Devogelaer, JP | 1 |
| Saag, K | 1 |
| Lau, CS | 1 |
| Reginster, JY | 1 |
| Papanastasiou, P | 1 |
| Bucci-Rechtweg, C | 1 |
| Su, G | 1 |
| Sambrook, PN | 1 |
| Oliveri, B | 1 |
| Di Gregorio, S | 1 |
| Parisi, MS | 1 |
| Solís, F | 1 |
| Mautalen, C | 1 |
| Inaoui, R | 1 |
| Petit, B | 1 |
| Jaccard, A | 1 |
| Bertin, P | 1 |
| Trèves, R | 1 |
| Van Staa, TP | 1 |
| Laan, RF | 1 |
| Barton, IP | 1 |
| Cohen, S | 1 |
| Cooper, C | 1 |
| Hurley, M | 1 |
| Yao, W | 1 |
| Lane, NE | 3 |
| Sosa, M | 1 |
| Jódar, E | 1 |
| Saavedra, P | 1 |
| Navarro, MC | 1 |
| Gómez de Tejada, MJ | 1 |
| Martín, A | 1 |
| Peña, P | 1 |
| Gómez, J | 1 |
| West, SG | 1 |
| Troutner, JL | 1 |
| Baker, MR | 1 |
| Place, HM | 1 |
| Mulder, H | 2 |
| Struys, A | 1 |
| Collins, LC | 1 |
| Peiris, A | 1 |
| Thompson, JM | 1 |
| Modin, GW | 2 |
| Arnaud, CD | 1 |
| Aagaard, EM | 1 |
| Lin, P | 1 |
| Struijs, A | 1 |
| Smals, A | 1 |
| de Witte, SA | 1 |
| Hackeng, WH | 1 |
| Weinstein, RS | 1 |
| Manolagas, SC | 1 |
| Lakshminarayanan, S | 1 |
| Walsh, S | 1 |
| Mohanraj, M | 1 |
| Rothfield, N | 1 |
| Le Gars, L | 1 |
| Grandpierre, C | 1 |
| Chazouillères, O | 1 |
| Berenbaum, F | 1 |
| Poupon, R | 1 |
| Lukert, BP | 1 |
| Johnson, BE | 1 |
| Robinson, RG | 1 |
| Maluje, V | 1 |
| Alvarado, A | 1 |
| Guzmán, L | 1 |
| Felder, M | 1 |
| Rüegsegger, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study[NCT00371956] | Phase 4 | 114 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial[NCT04034199] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-08-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prednisone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Apoptosis and osteoporosis.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Apoptosis; Bone Regeneration; Bone Remod | 2000 |
7 trials available for prednisone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Cross-Sectional Studies | 2020 |
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration | 2011 |
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration | 2011 |
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration | 2011 |
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration | 2011 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Densi | 2003 |
Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Bone Density | 2005 |
Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Bone Density; Drug Administration Schedule; Etidro | 1994 |
Acute effects of etidronate on glucocorticoid-induced bone degradation.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcium; Drug Therapy, Combination; Etidronic Acid; Female; Hom | 2000 |
16 other studies available for prednisone and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy.
Topics: Administration, Oral; Bone Density Conservation Agents; Cyclosporine; Female; Glucocorticoids; Human | 2019 |
Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis.
Topics: Abscess; Administration, Oral; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw | 2015 |
Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazol | 2010 |
[Strontium ranelate-induced DRESS syndrome].
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Biopsy; Bone Density Conservation | 2011 |
Is ultrasound of bone relevant for corticosteroid-treated patients? A comparative study with bone densitometry measured by DEXA.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcaneus; Dose-Respo | 2003 |
Aggressive systemic mastocytosis.
Topics: Aged; Alendronate; Bone Marrow Cells; Fatal Outcome; Female; Humans; Interferon-alpha; Leukemia, Mye | 2003 |
Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes
Topics: Absorptiometry, Photon; Aged; Bone Density; Cross-Sectional Studies; Female; Glucocorticoids; Humans | 2008 |
Sacral insufficiency fractures in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Causality; Female; Fractures, Stress; Humans; Middle Aged; Osteo | 1994 |
Bronchospasm secondary to replacement estrogen therapy.
Topics: Bronchial Spasm; Estrogen Replacement Therapy; Estrogens; Female; Forced Expiratory Volume; Humans; | 1993 |
Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density.
Topics: Absorptiometry, Photon; Aged; Anti-Inflammatory Agents; Bone Density; Estrogen Replacement Therapy; | 1997 |
Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Calcium; Estrogen Replacement Therapy; Fem | 1999 |
Factors associated with low bone mineral density in female patients with systemic lupus erythematosus.
Topics: Absorptiometry, Photon; Activities of Daily Living; Adolescent; Adult; Aged; Bone Density; Child; Co | 2001 |
Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Estrogen Replacement Therapy; Female; Glucocortic | 2002 |
Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Estrogen Replacement Therapy; Estrogens, Conjugat | 1992 |
[Spontaneous fracture of the sacrum in patient with pulmonary fibrosis and steroid treatment].
Topics: Chloroquine; Female; Fractures, Spontaneous; Humans; Middle Aged; Naproxen; Osteoporosis, Postmenopa | 1991 |
Bone loss in patients with rheumatoid arthritis--effect of steroids measured by low dose quantitative computed tomography.
Topics: Adult; Aged; Arthritis, Rheumatoid; Bone Density; Female; Humans; Menopause; Middle Aged; Osteoporos | 1991 |